Information Provided By:
Fly News Breaks for February 14, 2018
NBIX
Feb 14, 2018 | 07:53 EDT
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $100 from $95 to reflect Q4 financial results, management guidance on expenses and profitability. The analyst reiterates an Outperform rating on the shares.
News For NBIX From the Last 2 Days
There are no results for your query NBIX